BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords L, Schaefers C, Kamili A, Hoffmann C, Cichutek S, Haag F, Polywka S, Bokemeyer C, Leypoldt L, Alsdorf W, Schulze zur Wiesch J, Weisel K
HAEMATOLOGICA. 2024;109(9):3071-3077.

Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis
Seidel C, Schaefers C, Connolly E, Weickhardt A, Grimison P, Wong V, De Giorgi U, Hentrich M, Zschäbitz S, Ochsenreither S, Vincenzi B, Oing C, Bokemeyer C, Engel N, Alsdorf W, Tran B
ESMO OPEN. 2024;9(5):103449.

Broadening the horizon: potential applications of CAR-T cells beyond current indications
Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A
FRONT IMMUNOL. 2023;14:1285406.

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, Lüke F, Kutsch N, Müller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter A, Schulz-Eying C, Finlayson A, Flemmig C, Kühlcke K, Preußner L, Rengstl B, Türeci Ö, Şahin U
NAT MED. 2023;29(11):2844-2853.

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
Amsberg G, Zilles M, Mansour W, Gild P, Alsdorf W, Kaune M, Böckelmann L, Hauschild J, Krisp C, Rohlfing T, Saygi C, Alawi M, Zielinski A, Langebrake C, Su X, Perner S, Tilki D, Schluter H, Graefen M, Dyshlovoy S, Bokemeyer C
INT J MOL SCI. 2022;23(23):.

Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation
Ghandili S, Kluger M, Leitner T, Grahammer F, Kirchner L, Modemann F, Achilles E, Kreipe H, Klein J, Steinemann D, Wolschke C, Fischer L, Bokemeyer C, Fiedler W, Huber T, Alsdorf W, Mahmud M
BRIT J HAEMATOL. 2022;198(1):199-202.

Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine
Klingler F, Alsdorf W, Ghandili S, Wolschke C, Brauneck F, Bokemeyer C, Fiedler W, Modemann F, Karagiannis P
LEUKEMIA LYMPHOMA. 2022;63(11):2645-2651.

Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients
Madanchi R, Engel N, Alsdorf W, Oing C, Frenzel C, Paulsen F, Bokemeyer C, Seidel C
BONE MARROW TRANSPL. 2022;57(5):729-733.

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M
CANCER CELL. 2022;40(6):581-583.

Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S, Graefen M, Bokemeyer C, Merkens L, Dyshlovoy S
INT J MOL SCI. 2022;23(5):.

Kardiale Toxizität antineoplastischer Substanzen
Alsdorf W, Beitzen-Heineke A, Schmid P, Suter T, Bokemeyer C
2021.

Renale Toxizität antineoplastischer Substanzen
Alsdorf W, Bokemeyer C, Lipp H
2021.

Standardized supportive care documentation improves safety of high-dose methotrexate treatment
Alsdorf W, Karagiannis P, Langebrake C, Bokemeyer C, Frenzel C
ONCOLOGIST. 2021;26(2):e327-e332.

Prävention der Harnsäurenephropathie
Alsdorf W, Sökler M, Bokemeyer C
2021.

Begleittherapie bei Methotrexat
Alsdorf W, Sökler M, Jaehde U, Bokemeyer C
2021.

Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone
Karagiannis P, Alsdorf W, Tallarek A, Blohm M, Oelrich J, Waizenegger J, Wolschke C, Hecher K, Singer D, Bokemeyer C, Fiedler W
BRIT J HAEMATOL. 2021;192(2):e60-e63.

Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis
Karagiannis P, Sänger L, Alsdorf W, Weisel K, Fiedler W, Kluge S, Wichmann D, Bokemeyer C, Fuhrmann V
CANCERS. 2020;12(6):.

Successful Treatment of Delayed Methotrexate Clearance using Glucarpidase Dosed on Ideal Body Weight in Obese Patients
Krüger C, Engel N, Reinert J, Alsdorf W, Fiedler W, Dierlamm J, Bokemeyer C, Langebrake C
PHARMACOTHERAPY. 2020;40(5):479-483.

Current pharmacotherapy for testicular germ cell cancer
Alsdorf W, Seidel C, Bokemeyer C, Oing C
EXPERT OPIN PHARMACO. 2019;20(7):837-850.

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells
El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges T, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P
CLIN CHEM. 2018;64(3):536-546.

Treatment of Metastatic Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE) - Long-Term Disease Control by Multimodal Therapy
Quidde J, Alsdorf W, von Amsberg G, Wilczak W, Bokemeyer C
ONCOL RES TREAT. 2018;41(1-2):58-60.

Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Dulz S, Asselborn N, Dieckmann K, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger L, Alsdorf W, Mankichian B, Meyer C, Vetterlein M, Gild P, Ludwig T, Soave A, Schriefer P, Becker A, Ahyai S, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun F, Kluth L
J CANCER RES CLIN. 2017;143(7):1319-1325.

The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells
Dyshlovoy S, Madanchi R, Hauschild J, Otte K, Alsdorf W, Schumacher U, Kalinin V, Silchenko A, Avilov S, Honecker F, Stonik V, Bokemeyer C, von Amsberg G
BMC CANCER. 2017;17(1):93.

Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin
Dyshlovoy S, Otte K, Venz S, Hauschild J, Junker H, Makarieva T, Balabanov S, Alsdorf W, Madanchi R, Honecker F, Bokemeyer C, Stonik V, von Amsberg G
PROTEOMICS. 2017;17(11):.

Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells
Dyshlovoy S, Rast S, Hauschild J, Otte K, Alsdorf W, Madanchi R, Kalinin V, Silchenko A, Avilov S, Dierlamm J, Honecker F, Stonik V, Bokemeyer C, von Amsberg G
LEUKEMIA LYMPHOMA. 2017;58(12):2905-2915.

Platinum-refractory germ cell tumors: an update on current treatment options and developments
Oing C, Alsdorf W, von Amsberg G, Oechsle K, Bokemeyer C
WORLD J UROL. 2017;35(8):1167-1175.

Cisplatin-refraktäre Keimzelltumoren: Resistenzmechanismen − Therapiestandards − neue Entwicklungen
Oing C, Seidel C, Alsdorf W, Bokemeyer C
ONKOLOGE. 2017;23(2):123-128.

Cisplatin-refraktäre Keimzelltumoren: Resistenzmechanismen − Therapiestandards − neue Entwicklungen
Oing C, Seidel C, Alsdorf W, Bokemeyer C
ONKOLOGE. 2017;23(2):123-128.

Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
Alsdorf W, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M
J ONCOL PHARM PRACT. 2016;22(3):523-7.

The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer
Dyshlovoy S, Menchinskaya E, Venz S, Rast S, Amann K, Hauschild J, Otte K, Kalinin V, Silchenko A, Avilov S, Alsdorf W, Madanchi R, Bokemeyer C, Schumacher U, Walther R, Aminin D, Fedorov S, Shubina L, Stonik V, Balabanov S, Honecker F, von Amsberg G
INT J CANCER. 2016;138(10):2450-65.

Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer
Dyshlovoy S, Otte K, Alsdorf W, Hauschild J, Lange T, Venz S, Bauer C, Bähring R, Amann K, Mandanchi R, Schumacher U, Schröder-Schwarz J, Makarieva T, Guzii A, Tabakmakher K, Fedorov S, Shubina L, Kasheverov I, Ehmke H, Steuber T, Stonik V, Bokemeyer C, Honecker F, von Amsberg G
ONCOTARGET. 2016;7(43):69703 - 69717.

Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.
Alsdorf W, Clauditz T, Hoenig T, Quaas A, Sirma H, Koenig A, Izbicki J, Sauter G, Marx A, Grob T
EXP MOL PATHOL. 2013;94(1):155-159.

Letzte Aktualisierung aus dem FIS: 24.12.2024 - 04:03 Uhr